Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503402 | 0.84 | CLK1 (0.36) | MAOBALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL4514403 | 0.70 | KDM4E (0.41) | MAOBACHEALDH1A1HPGDHSD17B10 | |
| SCHEMBL3868211 | 0.70 | CYP1A2 (0.49) | ACHEALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL4501372 | 0.68 | KMT2A (0.45) | MAOBACHEALDH1A1HPGDHSD17B10 | |
| SCHEMBL1502392 | 0.67 | ALDH1A1 (0.62) | MAOBACHEALDH1A1HPGDHSD17B10 | |
| SCHEMBL4501473 | 0.67 | NCF1 (0.50) | MAOBACHEALDH1A1HPGDHSD17B10 | |
| SCHEMBL30543754 | 0.67 | RAB9A (0.53) | MAOBACHEALDH1A1HPGDHSD17B10 | |
| SCHEMBL9601916 | 0.67 | RAB9A (0.53) | MAOBACHEALDH1A1HPGDHSD17B10 | |
| SCHEMBL13400206 | 0.65 | ALDH1A1 (0.59) | MAOBACHEALDH1A1HPGDHSD17B10 | |
| SCHEMBL321429 | 0.64 | METAP1 (0.58) | ACHEALDH1A1HPGDHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174983-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-04-25 | — | — | US | disclosed |
| EP-3906233-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023235490-A1 | COMBINATION THERAPY WITH IMMUNOMODULATORS, DYRK1A INHIBITORS, AND GLP1R AGONISTS FOR TYPE 1 DIABETES TREATMENT | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
| EP-3717475-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| US-5814642-A | CHOLINESTERASE INHIBITORY COMPOSITION FOR TREATMENT OF SENILE DEMENTIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-29 | — | — | US | disclosed |
| US-5620973-A | CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0655451-A1 | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, DYRK1A, CSNK1G3 | MAOB 1518/4885ACHE 745/4885ALDH1A1 4559/4885 |
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | MAOB 1416/4885ACHE 574/4885ALDH1A1 4635/4885 |
| US-20240174983-A1 | METHOD OF INCREASING PROLIFERATION OF PANCREATIC BETA CELLS, TREATMENT METHOD, AND COMPOSITION | IAPP, DYRK1A, GLP1R | MAOB 1989/4885ACHE 1494/4885ALDH1A1 3491/4885 |
| US-11547712-B2 | Kinase inhibitor compounds and compositions and methods of use | MAP3K20, MAP3K1, PACSIN2 | MAOB 1868/4885ACHE 620/4885ALDH1A1 4750/4885 |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | IAPP, GLP1R, GPR119 | MAOB 2146/4885ACHE 1445/4885ALDH1A1 3769/4885 |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | MAOB 1417/4885ACHE 443/4885ALDH1A1 4726/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | MAOB 259/4885ACHE 1/4885ALDH1A1 1185/4885 |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | CSNK1A1, CSNK1E, CSNK1G3 | MAOB 1294/4885ACHE 831/4885ALDH1A1 4302/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | MAOB 944/4885ACHE 8/4885ALDH1A1 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.